NEW YORK ( TheStreet) -- Pharmaceutical company Bristol-Myers Squibb ( BMY) expects non-GAAP earnings of at least $1.95 a share for 2013, saying that it is "well-positioned to deliver on the promise of our pipeline." Bristol-Myers Squibb also expects 2013 to be the first full year of impact from the loss of its Plavix patent exclusivity in the U.S., it said in a statement. However, the company expects to sustain growth in 2014 and beyond. The 2013 figure excludes any potential impact of U.S. healthcare reform. -- Reported by Andrea Tse in New York Follow TheStreet.com on Twitter and become a fan on Facebook.